We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AstraZeneca, BMS Submit Onglyza NDA for Type 2 Diabetes
AstraZeneca, BMS Submit Onglyza NDA for Type 2 Diabetes
July 25, 2008
Bristol-Myers Squibb and AstraZeneca have submitted an NDA to the FDA, along with a marketing authorization application to the European Medicines Agency, for their new Type 2 diabetes drug Onglyza.